A examine at the moment in JAMA Community Open from the College of California, San Francisco (UCSF), exhibits a excessive uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody nirsevimab amongst pregnant ladies seen in the course of the 2023-24 season, the primary RSV season the vaccine and drug have been accessible.
A second examine, additionally revealed at the moment in the identical journal, checked out sufferers seen on the Beth Israel Deaconess Medical Heart in Boston and located a decrease uptake of maternal RSV vaccine and nirsevimab (Beyfortus) throughout the identical preliminary season, however greater than half of infants studied have been protected.
Vaccine uptake a lot larger in COVID-vaccinated ladies
The primary retrospective cohort examine included 647 eligible pregnant ladies, with a median age of 34.6 years. Of the 647 sufferers, 414 (64.0%) acquired Pfizer’s RSV prefusion F protein–primarily based (RSVpreF) vaccine throughout being pregnant. The vaccine is commercially accessible as Abrysvo.
A number of elements have been related to excessive maternal uptake of the vaccine, together with older age of the mom (adjusted odds ratio [AOR]1.09; 95% confidence interval [CI]1.05 to 1.12), and having no prior pregnancies or youngsters (AOR, 1.84; 95% CI, 1.31 to 2.60). Notably, maternal receipt of any COVID-19 vaccine was extremely related to RSV vaccine uptake (AOR, 7.12; 95% CI, 3.91 to 13.70).
Elements related to decrease odds of receiving maternal RSV vaccination included non-English language desire (AOR, 0.24; 95% CI, 0.10 to 0.52) and Black race (AOR, 0.30; 95% CI, 0.16 to 0.57).
The examine additionally checked out nirsevimab use amongst 261 eligible infants previous to hospital discharge. Nirsevimab was administered to 183 of 261 eligible infants (70.1%). The authors mentioned nirvesimab was accepted even amongst dad and mom who had declined different routine prenatal or toddler vaccines.
“Amongst those that didn’t obtain RSVpreF or customary prenatal vaccines, 40.4% of their neonates (19 of 47) acquired nirsevimab; amongst those that declined toddler hepatitis B vaccination, 34.0% of their neonates (17 of fifty) acquired nirsevimab,” the authors wrote.
RSV-protective protection, through both maternal vaccine or toddler nirsevimab administration exceeded 80% in all examine months, besides the primary examine month, October 2023.
“This examine means that an RSV prevention technique that included each prenatal vaccination and toddler monoclonal antibody administration had excessive uptake and reassuring perinatal outcomes,” the authors concluded.
Over half of infants protected
Within the second examine, 20.5% of moms and 35.0% of infants acquired RSV immunizations on the Beth Israel Deaconess Medical Heart from September 1, 2023, to January 31, 2024.
Amongst 1,940 reside births seen on the hospital, 54.8% of infants acquired RSV safety, of which 65.5% acquired safety after delivery. The proportion of infants receiving RSV safety elevated every month, from 27.1% in September 2023 to 77.7% in January 2024.
On the finish of the RSV season, 389 maternal sufferers (20.5%) had acquired RSVpreF and 665 infants (35.0%) acquired nirsevimab.
Variations in maternal vaccine charges throughout race and ethnicity classes persevered all through the RSV season; nonetheless, race-based disparities in nirsevimab administration decreased.
“Variations in maternal vaccine charges throughout race and ethnicity classes persevered all through the RSV season; nonetheless, race-based disparities in nirsevimab administration decreased,” the authors mentioned. “Disparities in maternal, however not toddler, vaccination persevered all through the examine.”
